INOVIO Expects About $80.5 Million From Stock Offering To Fund DNA Medicine Development
Management expects the proceeds and existing cash resources to cover operations and capital spending into late fourth quarter 2027.
INOVIO Pharmaceuticals, which develops DNA medicines for HPV-related diseases, cancer and infectious diseases, expects about $80.5 million after offering costs, including an additional-share option that underwriters exercised in full Friday. In its Monday SEC filing, management said the proceeds and existing cash resources should cover operations and capital spending into late fourth quarter 2027.
New Shares And Prepaid Warrants
INOVIO priced the offering Thursday, setting the common-share price at $1.05. The base sale consists of 58,747,235 common shares and largely prepaid warrants covering 12,681,337 shares.
Buyers pay $1.049 for each warrant and another $0.001 per share when exercising it. The rights can be exercised until used in full. For existing holders, issuing new shares means their shares represent a smaller portion of the company; warrant exercises would add shares as well.
Jefferies and Piper Sandler jointly manage the offering, with H.C. Wainwright serving as lead manager. All the securities are being sold by INOVIO, rather than existing shareholders.
The Option Expands The Sale
The underwriters committed Friday to buy 10,714,285 additional shares, using the full option available under the offering agreement. INOVIO's approximately $80.5 million expected net proceeds account for those shares, underwriting fees and estimated offering expenses.
The company's Thursday pricing announcement put expected gross proceeds at approximately $75 million. That figure excluded the additional-share option and was before fees and expenses, so it measures a different scope from the net estimate.
INOVIO had filed the framework for future securities sales on July 2, 2026. It became effective July 10, 2026, and the company used a supplemental prospectus for this offering.
Funding A Research-Stage Business
INOVIO's lead candidate, INO-3107, targets recurrent respiratory papillomatosis, a rare illness that produces airway tumors. Its other candidates include treatments aimed at throat cancer and other cancers.
The medicines use plasmids—small circular DNA molecules—to tell cells to produce specific proteins. CELLECTRA devices help deliver that DNA into cells using short electrical pulses. The company's DNA medicines have been administered over 19,000 times to nearly 6,000 participants, according to its annual report for 2025.
All candidates remain in research and development. INOVIO has earned no product-sales revenue; its revenue comes from licensing, milestone payments and collaborative research arrangements.
Management's funding estimate combines the offering proceeds with cash, cash equivalents and short-term investments. The company expects those resources to meet its operating and capital needs into late fourth quarter 2027, based on its planned use of the money.
The offering is expected to close on or about Monday; the $80.5 million remains an expected net amount, rather than completed financing.
Sources
- 8-K Filing — INOVIO PHARMACEUTICALS, INC. (INO) — SEC EDGAR
- Exhibit d192373dex991.htm — INOVIO PHARMACEUTICALS, INC. 8-K exhibit — SEC EDGAR
- Exhibit d192373dex992.htm — INOVIO PHARMACEUTICALS, INC. 8-K exhibit — SEC EDGAR
- INOVIO Announces Proposed Public Offering of its Common Stock — prnewswire.com
- INOVIO Announces Pricing of Approximately $75 Million Public Offering — prnewswire.com
